HOME >> BIOLOGY >> NEWS
Phase III clinical program evaluates lubiprostone

BETHESDA, MD May 16, 2005 Takeda Pharmaceuticals North America (TPNA) and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome (IBS-C). Enrollment for these trials begins this month. Lubiprostone is an investigational compound currently being evaluated by the FDA for the treatment of chronic idiopathic constipation and associated pain and bloating in adults.

The IBS-C clinical development program will include two phase III trials. Each trial will examine more than 500 patients for 12 weeks to evaluate the safety and efficacy of lubiprostone.

"Irritable bowel syndrome is a condition that can impact a person's quality of life, but is currently addressed by few available therapies," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine, and principal investigator. "Based on results from our phase II study, we believe lubiprostone may have the potential to treat IBS-C, and thus offer a new option for people living with irritable bowel syndrome."

The program includes two double-blind, randomized phase III clinical trials with a treatment period of 12 weeks, taking place at up to 130 sites around the United States. A previous phase II study in IBS-C patients evaluated the effectiveness across a range of doses. Additionally, studies of lubiprostone in chronic constipation have achieved clinical endpoints of relief of constipation and associated pain and bloating and demonstrated tolerability, regardless of gender.

Lubiprostone is a chloride channel activator, a novel compound with a unique mechanism of action. Taken orally, the agent has been shown to work locally and specifically in the GI tract by activating a specific chloride channel (CLC2). Chloride channels are proteins that carry chloride on cells lining the small intestine. When activated, these cells increase in
'"/>


16-May-2005


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
3. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
6. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
7. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
8. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
9. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
10. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
11. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... ... December 05, 2018 , ... ... Medicine’s Photodynamic Therapy symposium 2018, London, England. The 2018 PDT symposium was organized ... of PDT and its benefits in clinical practice across a range of applications ...
(Date:12/5/2018)... ... December 04, 2018 , ... Urological ... as a UroLift® Center of Excellence. The designation recognizes that Dr. Choi has ... demonstrated a commitment to exemplary care for men suffering from symptoms associated with ...
(Date:11/29/2018)... , ... November 29, 2018 , ... ... excited to collaborate with the new NSF Engineering Research Center for Cell ... collaborators brought together to develop transformative tools and technologies for the consistent, scalable ...
Breaking Biology News(10 mins):
(Date:11/9/2018)... (PRWEB) , ... November 08, 2018 , ... ... integrator of custom industrial automation and IT solutions with 140 employees on both ... Automation Fair®, taking place at the Pennsylvania Convention Center on November 14 and ...
(Date:11/7/2018)... ... November 07, 2018 , ... Diversified Technologies, Inc. ... at AzCATI, the Arizona Center for Algae Technology and Innovation at ASU. Funded by ... and trials for those involved with algal and predator control applications. , Algae ponds ...
(Date:11/5/2018)... FREDERICK, Md. (PRWEB) , ... November 05, 2018 ... ... up with a regional higher education center to increase access to science research ... and Education in Science and Technology (CREST) aims to provide access to STEM-based ...
(Date:11/5/2018)... ... November 05, 2018 , ... GlycoMark, Inc., ... healthcare professionals through its website, http://www.glycomark.com , as part of National Diabetes ... video option via the website in November from 9 a.m. – 5 p.m. ...
Breaking Biology Technology:
Cached News: